Company: RDPTF
Filing Date: 2025-09-18
Form Type: 20-F
Source: 0001213900-25-088699
Chunk: 103

Company: Radiopharm Theranostics Ltd
Filing Date: 2025-09-18
Form: 20-F
Item: Item 6
Chunk 103
---
 approvals of Tagrisso®, Opdivo®,
Tasigna®, and Caelyx®. As Head of Oncology Early Clinical Development at AstraZeneca, she oversaw the company’s early oncology
portfolio. Dr. Alland received her B. A from the University of Pennsylvania and M. D. from New York University. She completed training
in Pediatrics at the Children’s Hospital of Philadelphia, and Hematology/Oncology at Memorial Sloan-Kettering, and served on the
faculty of Albert Einstein College of Medicine during which she received multiple grants and awards for her research on oncoproteins
and epigenetics.

Ian Turner. Ian Turner
has been a Director of Radiopharm since February 2021. Since August 2022, he is also non-executive director at AtomVie Global Radiopharma
Inc, a global contract development and manufacturing organization, launched by the Centre for Probe Development and Commercialisation
(CPDC). Mr. Turner was a director of Coqui Pharmaceuticals from November 2014 to March 2019. Mr. Turner was Chief Executive Officer at
Siemens Radiopharmaceuticals, which operated a large global PET radio-pharmacy network, from 2010 to 2012. Prior to that, he was General
Manager of ANSTO Radiopharmaceuticals, which was Australia’s leading manufacturer of radioisotopes for the nuclear medicine sector.
Since 2013, Mr. Turner is the CEO of the Turner Group LLC, a boutique management consulting firm that advises institutional investors
on acquisition targets in the field of nuclear medicine, radiochemicals and radiopharmaceuticals.

Phillip Hains. Phillip
Hains has served as our Chief Financial Officer and Joint Company Secretary since February 2021 and as a Director since March 2024. Mr.
Hains is a member of Chartered Accountants Australia and New Zealand (CAANZ), with over three decades of professional experience in roles
across a range of ASX- and Nasdaq-listed, as well as unlisted, companies. He holds a Master of Business Administration from RMIT University.

Noel Donnelly. Noel
Donnelly has been a Director of Radiopharm since late September 2024. Mr. Donnelly is a finance and R& D executive with leadership
experience in strategy, portfolio management, financial planning and analysis; project management, business partnering, valuation, decision
support analysis as well as building, leading and managing